Abstract submission is now closed
View the abstracts in the online programme
Abstract submission deadlines
Date and time
Tuesday, 17 January 2023, 21:00 CET (Central European Time)
Wednesday, 01 March 2023, 21:00 CET (Central European Time)
A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on 17 January 2023.
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters between 6 and 10 February 2023.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters between 6 and 10 March 2023.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by mid-February in the section “Information for Presenters”.
Abstract submission categories
- Tumour biology and pathology
- Translational research
- Prevention, early detection, epidemiology, tobacco control
- Imaging and staging
- Early stage NSCLC
- Locally advanced NSCLC
- Advanced NSCLC
- Metastases to and from the lung
- General interest
Late-breaking abstracts (LBA)
Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 01 March 2023 is under no circumstances to be considered as an extension of the general submission deadline.
Trial in progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2023.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The ELCC 2023 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:
- Proffered Paper: Oral presentation of original data of superior quality, followed by expert discussion and perspectives
- Mini Oral: Short oral presentation of good quality data, followed by expert discussion and perspectives.
- Poster: Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts will be published in the ELCC 2023 Abstract book, a supplement to the official IASLC journal, Journal of Thoracic Oncology.
Publication schedule for accepted abstracts
Details regarding the publication of accepted abstracts are available here.
Merit Travel Grants
A limited number of Merit Travel Grants to ELCC 2023 are available, upon application, to first authors under the age of 40 (forty) who submit abstracts considered deserving of recognition. Selection will be made by the ELCC 2023 Scientific Committee on a competitive basis from among the accepted abstracts.